{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:02:38Z","timestamp":1790960558729,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ30874"],"award-info":[{"award-number":["2022JJ30874"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10637-024-01472-w","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T09:04:12Z","timestamp":1726131852000},"page":"575-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia"],"prefix":"10.1007","volume":"42","author":[{"given":"Liping","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoquan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"1","key":"1472_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41392-022-01022-x","volume":"7","author":"Y Luo","year":"2022","unstructured":"Luo Y, Sun N, He J (2022) Nivolumab plus Ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC. Signal Transduct Target Ther 7(1):169. https:\/\/doi.org\/10.1038\/s41392-022-01022-x","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1472_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"1472_CR3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1056\/NEJMcp1810479","volume":"381","author":"N Cooper","year":"2019","unstructured":"Cooper N, Ghanima W, Immune Thrombocytopenia (2019) N Engl J Med 381(10):945\u2013955. https:\/\/doi.org\/10.1056\/NEJMcp1810479","journal-title":"N Engl J Med"},{"issue":"21","key":"1472_CR4","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","volume":"129","author":"MP Lambert","year":"2017","unstructured":"Lambert MP, Gernsheimer TB (2017) Clinical updates in adult immune thrombocytopenia. Blood 129(21):2829\u20132835. https:\/\/doi.org\/10.1182\/blood-2017-03-754119","journal-title":"Blood"},{"issue":"10","key":"1472_CR5","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the Immune-related adverse effects of Immune Checkpoint inhibitors: a review. JAMA Oncol 2(10):1346\u20131353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051","journal-title":"JAMA Oncol"},{"key":"1472_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","volume":"122","author":"JM Michot","year":"2019","unstructured":"Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M et al (2019) Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer 122:72\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.014","journal-title":"Eur J Cancer"},{"issue":"Suppl 2","key":"1472_CR7","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1053\/j.seminoncol.2015.09.017","volume":"42","author":"MA Socinski","year":"2015","unstructured":"Socinski MA (2015) Incorporating Immunotherapy into the treatment of Non-small Cell Lung Cancer: practical Guidance for the clinic. Semin Oncol 42(Suppl 2):S19\u201328. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.09.017","journal-title":"Semin Oncol"},{"issue":"21","key":"1472_CR8","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691\u20132697. https:\/\/doi.org\/10.1200\/JCO.2012.41.6750","journal-title":"J Clin Oncol"},{"issue":"6","key":"1472_CR9","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1177\/1078155220981155","volume":"27","author":"S Fu","year":"2021","unstructured":"Fu S, Wang T, Xu F (2021) Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: a case report and literature review. J Oncol Pharm Pract 27(6):1548\u20131552. https:\/\/doi.org\/10.1177\/1078155220981155","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"1472_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","volume":"7","author":"MA Couey","year":"2019","unstructured":"Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD et al (2019) Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7(1):165. https:\/\/doi.org\/10.1186\/s40425-019-0645-6","journal-title":"J Immunother Cancer"},{"issue":"19","key":"1472_CR11","doi-asserted-by":"publisher","first-page":"e59125","DOI":"10.1172\/jci.insight.59125","volume":"3","author":"A Osa","year":"2018","unstructured":"Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3(19):e59125. https:\/\/doi.org\/10.1172\/jci.insight.59125","journal-title":"JCI Insight"},{"issue":"7","key":"1472_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","volume":"58","author":"M Centanni","year":"2019","unstructured":"Centanni M, Moes DJAR, Troc\u00f3niz IF, Ciccolini J, van Hasselt JGC (2019) Clinical pharmacokinetics and pharmacodynamics of Immune Checkpoint inhibitors. Clin Pharmacokinet 58(7):835\u2013857. https:\/\/doi.org\/10.1007\/s40262-019-00748-2","journal-title":"Clin Pharmacokinet"},{"key":"1472_CR13","doi-asserted-by":"publisher","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol.; 28(19):3167-75. doi: 10.1200\/JCO.2009.26.7609. Epub 2010 Jun 1. Corrected and republished in: J Clin Oncol. 2023;41(4):715\u2013723. https:\/\/doi.org\/10.1200\/JCO.22.02270","DOI":"10.1200\/JCO.22.02270"},{"key":"1472_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","volume":"5","author":"E Shiuan","year":"2017","unstructured":"Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J et al (2017) Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer 5:8. https:\/\/doi.org\/10.1186\/s40425-017-0210-0","journal-title":"J Immunother Cancer"},{"key":"1472_CR15","doi-asserted-by":"publisher","first-page":"100822","DOI":"10.1016\/j.blre.2021.100822","volume":"49","author":"M Kochhar","year":"2021","unstructured":"Kochhar M, Neunert C (2021) Immune Thrombocytopenia: a review of upfront treatment strategies. Blood Rev 49:100822. https:\/\/doi.org\/10.1016\/j.blre.2021.100822","journal-title":"Blood Rev"},{"issue":"2","key":"1472_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/jcm6020016","volume":"6","author":"A Zufferey","year":"2017","unstructured":"Zufferey A, Kapur R, Semple JW (2017) Pathogenesis and therapeutic mechanisms in Immune Thrombocytopenia (ITP). J Clin Med 6(2):16. https:\/\/doi.org\/10.3390\/jcm6020016","journal-title":"J Clin Med"},{"key":"1472_CR17","doi-asserted-by":"publisher","first-page":"101170","DOI":"10.1016\/j.rmcr.2020.101170","volume":"31","author":"J Sakakibara-Konishi","year":"2020","unstructured":"Sakakibara-Konishi J, Sato M, Sato MT, Kasahara K, Onozawa M, Mizugaki H, Kikuchi E, Asahina H, Shinagawa N, Konno S (2020) Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma. Respir Med Case Rep 31:101170. https:\/\/doi.org\/10.1016\/j.rmcr.2020.101170","journal-title":"Respir Med Case Rep"},{"issue":"44","key":"1472_CR18","doi-asserted-by":"publisher","first-page":"27460","DOI":"10.18632\/oncotarget.25446","volume":"9","author":"V Rolfes","year":"2018","unstructured":"Rolfes V, Idel C, Pries R, Pl\u00f6tze-Martin K, Habermann J, Gemoll T et al (2018) PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. Oncotarget 9(44):27460\u201327470. https:\/\/doi.org\/10.18632\/oncotarget.25446","journal-title":"Oncotarget"},{"issue":"6","key":"1472_CR19","first-page":"612","volume":"85","author":"RL Gauer","year":"2012","unstructured":"Gauer RL, Braun MM, Thrombocytopenia (2012) Am Fam Physician 85(6):612\u2013622 PMID: 22534274","journal-title":"Am Fam Physician"},{"key":"1472_CR20","doi-asserted-by":"publisher","first-page":"109015","DOI":"10.1016\/j.intimp.2022.109015","volume":"110","author":"DC Moore","year":"2022","unstructured":"Moore DC, Elmes JB, Arnall JR, Strassels SA, Patel JN (2022) Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: a real-world study of the FDA adverse event reporting system. Int Immunopharmacol 110:109015. https:\/\/doi.org\/10.1016\/j.intimp.2022.109015","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"1472_CR21","doi-asserted-by":"publisher","first-page":"e00799","DOI":"10.1002\/rcr2.799","volume":"9","author":"O Kanai","year":"2021","unstructured":"Kanai O, Nakatani K, Fujita K, Okamura M, Mio T (2021) No need to hesitate: immune-related neutropenia and thrombocytopenia that improved by corticosteroids. Respirol Case Rep 9(7):e00799. https:\/\/doi.org\/10.1002\/rcr2.799","journal-title":"Respirol Case Rep"},{"issue":"17","key":"1472_CR22","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of Immune-related adverse events in patients treated with Immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"1472_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrc.2016.02.009","volume":"6","author":"SJ Bagley","year":"2016","unstructured":"Bagley SJ, Kosteva JA, Evans TL, Langer CJ (2016) Immune Thrombocytopenia exacerbated by Nivolumab in a patient with non-small-cell lung cancer. Cancer Treat Commun 6:20\u201323. https:\/\/doi.org\/10.1016\/j.ctrc.2016.02.009","journal-title":"Cancer Treat Commun"},{"issue":"10","key":"1472_CR24","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood.V91.10.3616","volume":"91","author":"S Nomura","year":"1998","unstructured":"Nomura S, Matsuzaki T, Ozaki Y, Yamaoka M, Yoshimura C, Katsura K et al (1998) Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura. Blood 91(10):3616\u20133622","journal-title":"Blood"},{"issue":"5","key":"1472_CR25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/bjh.15085","volume":"180","author":"T Kasamatsu","year":"2018","unstructured":"Kasamatsu T, Ino R, Takahashi N, Gotoh N, Minato Y, Takizawa M et al (2018) PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia. Br J Haematol 180(5):705\u2013714. https:\/\/doi.org\/10.1111\/bjh.15085","journal-title":"Br J Haematol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01472-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01472-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01472-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T09:11:17Z","timestamp":1733562677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01472-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01472-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Statement"}}]}}